Nuvation Bio (NUVB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Nuvation Bio (NUVB) is Neutral.

The composite score behind that read is -0.06, weighing +0.06 of bullish evidence against -0.23 bearish.

Nuvation Bio last closed at $5.00, +1.01% on the session.

Against the IVW growth benchmark the position is +0.21% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

Nuvation Bio has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Nuvation Bio in the 18th percentile on return on equity, where 100 is best.

Nuvation Bio is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.74B.

StockMap tracks Nuvation Bio as the 45th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Nuvation Bio ranks 72nd of 151 in the group, against a group median of -0.08.